Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
E-Power Resources Inc. Announces Closing of Oversubscribed Hard Dollar and Flow-through Private Placements